TFA Therapeutics (RAJAF) Notes Payables (2020 - 2025)

TFA Therapeutics has reported Notes Payables for 6 years, with the latest figure at $4.0 million in Q4 2025.

• On a quarterly basis, Notes Payables rose 3.0% year-over-year to $4.0 million in Q4 2025; TTM through Dec 2025 was $4.0 million, a 3.0% increase from a year earlier, with the FY2025 full-year figure at $4.0 million, up 3.0% from the prior year.
• Notes Payables was $4.0 million for Q4 2025 at TFA Therapeutics, up from $3.9 million in the prior quarter.
• The five-year high for Notes Payables was $4.0 million in Q4 2025, with the low at $62754.0 in Q4 2022.
• Average Notes Payables over 5 years is $2.4 million, with a median of $2.6 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Notes Payables sank 96.01% in 2022, then soared 4052.07% in 2023.
• Over 5 years, Notes Payables stood at $1.6 million in 2021, then tumbled by 96.01% to $62754.0 in 2022, then jumped by 4052.07% to $2.6 million in 2023, then jumped by 49.44% to $3.9 million in 2024, then grew by 3.0% to $4.0 million in 2025.
• The last three Notes Payables figures came in at $4.0 million (Q4 2025), $3.9 million (Q4 2024), and $2.6 million (Q4 2023), per Business Quant data.